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Introduction
Cerebrovascular disease is an important cause of
mortality and long-term disability in developed
countries [1]. In Italy, 10-12% of deaths are stroke-
related, with almost 196000 new cases/year [1]. The
vast majority of cerebrovascular events (nearly 80%)
are ischemic strokes, caused by the interruption of
arterial blood supply by an intravascular thrombus or
a migrant embolus, while an hemorrhagic nature ac-
counts for only the remaining 20% of the cases [1].
Atherosclerosis of the supra-aortic vessels, and espe-
cially of the common carotid bifurcation, is a major
cause of recurrent ischemic stroke, accounting for
approximately 20% of all strokes [2, 3]. 
Atherosclerotic lesions of common and internal
carotid arteries are frequent in general population,
and their incidence raises in the elderly population
[4]. Carotid plaques may produce cerebral ischemia
by three mechanisms: 1) arterial embolism of plaque
debris, 2) acute thrombotic occlusion or 3) reduced
cerebral perfusion resulting from critical stenosis or
occlusion caused by progressive plaque growth [5].
All these three mechanisms are able to induce cere-
bral ischemia, however neurological symptoms only
occur if the intracranial circulation becomes defi-
cient. Therefore, it is particularly important to dif-
ferentiate patients with symptoms arising from the
stenosis and cases of asymptomatic carotid obstruc-
tion, which may frequently be discovered after a
routine ultrasound exam of the supra-aortic trunks. 
According to the largest randomized clinical tri-
als, patients are considered symptomatic if they ex-
perienced a transient ischemic attack (TIA) or stroke
in the previous three months [6, 7]. Suggestive
symptoms of a carotid-related cerebrovascular event
include, but are not limited to, unilateral weakness
(up to paralysis), monolateral paresthesia or sensory
loss, hemineglect, non-fluent aphasia, abnormal vi-
sual-spatial ability, monocular blindness and
homonymous hemianopsia. In several studies the
annual risk of ipsilateral stroke in asymptomatic pa-
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Atherosclerotic stenosis of common and internal
carotid arteries is a well-recognized risk factor for ischemic
stroke, and revascularization has been proven to be the
main tool of prevention, particularly for patients with steno-
sis-related symptoms. While for many years surgical carotid
endarterectomy (CEA) has been considered the gold-stan-
dard strategy to restore vascular patency, recently the en-
dovascular treatment through percutaneous angioplasty
and stent implantation (CAS) has become a valid alterna-
tive. In the last years, interesting data about the comparison
of these strategies have emerged. CAS seems to cause more
peri-procedural strokes, but may also avoid many adverse
events related to surgery and general anaesthesia, including
peri-procedural myocardial infarction. For these reasons, it
was initially considered a second-choice strategy to be
adopted in patients for whom surgery was contraindicated.
However, more recent trials have shown that CAS might be
considered an effective alternative to CEA. Moreover, the
rapid evolution of CAS technique and materials suggests its
potential to improve outcome and possible superiority com-
pared to CEA in the next future. Purpose of this review is to
discuss the most recent clinical evidences concerning the
treatment of carotid artery stenosis, with a special focus on
the endovascular treatment.
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tients assigned to medical therapy alone is approxi-
mately 2% [8-11], however such risk increases in
the presence of the following conditions: elderly pa-
tients, controlateral carotid artery stenosis or occlu-
sion, evidence of silent embolization on brain imag-
ing, carotid plaque heterogeneity and poor collateral
blood supply [12]. In contrast, the risk of stroke in
symptomatic patients has been estimated to be about
13% per year [13]. Thus, the presence of symptoms
appears to be the most reliable criterion to decide an
appropriate strategy of intervention. 
For over fifty years the standard therapeutic
strategy for significant carotid artery stenosis has
been the surgical restoration of the arterial patency
by surgical removal of the plaque through en-
darterectomy. In the last twenty years an important
alternative has emerged, represented by the en-
dovascular treatment through angioplasty and stent
implantation. Even if the endovascular technique
has shown good efficacy, it has been considered for
many years only a second choice to surgery in pa-
tients presenting high co-morbidities or high peri-
operative risk due to anatomic factors. However,
these assumptions have recently been challenged by
the interesting results of the clinical trial Stenting
versus Endarterectomy for Treatment of Carotid-
Artery Stenosis (CREST), demonstrating no signifi-
cant differences between surgery and stenting in a
selected groups of patients [6]. 
The “classical” management of carotid stenosis:
medical therapy and surgical endarterectomy
Being carotid stenosis a well-recognized risk fac-
tor for cerebrovascular disease development, every
effort should be attempted in order to prevent such
serious complications. The first step for prevention is
based on non-pharmacological and pharmacological
recommendations to modify the classical risk-factors
for atherosclerosis: smoking cessation, blood pres-
sure control (particularly with dihydropyridines Ca-
antagonists [14]), plasma lipids lowering (by diet,
lifestyle and eventually by the administration of
statins [15-17]), adequate management of diabetes
[18] and metabolic syndrome and encouragement to
perform physical activity. In addition to these recom-
mendation, the American Heart Association (AHA)
guidelines propose the administration of antiplatelet
therapy (with schemes and dosages related to risk
factors, adverse reaction to drugs and risk of bleed-
ing) for all the patients with obstructive or non-ob-
structive lesions of the extracranial vessels responsi-
ble for brain vascularization. While for symptomatic
patients the benefit appears to be well demonstrated,
there is less evidence in favor of antiplatelet therapy
in asymptomatic patients with carotid stenosis [19].
Similarly, the European Society of Cardiology (ESC)
guidelines suggest the use of antiplatelet therapy re-
gardless of symptoms in all patients with an athero-
sclerotic lesion of a carotid vessel [20]. Moreover,
antiplatelet therapy for all patients with a carotid
stenosis seems to be advantageous in terms of pre-
vention of myocardial ischemia and infarction, even
though the efficacy against stroke is not completely
clear [19, 21-23]. The most commonly prescribed
anti-platelet regimens include aspirin at the dosage
of 75-325 mg/die, clopidogrel 75 mg/die, and even-
tually the association of these compounds in very
high-risk patients with multiple atherosclerotic le-
sions, as suggested by the results of the Clopidogrel
versus Aspirin in Patients at Risk of Ischaemic
Events (CAPRIE) study [24], or ticlodipine 250
mg/die. 
In patients with an asymptomatic carotid artery
stenosis greater than 50% under optimal medical
therapy (including anti-hypertensive drugs, statins
and aspirin or analogues), the annual event rates on
medical treatment are relatively low [10], suggesting
that the gold standard for such patients is medical
therapy. However, revascularization may be consid-
ered even in these patients for specific situations re-
lated to a high risk of complications based on intrin-
sic features of the lesion. The surgical treatment re-
stores the patency of the obstructed carotid and is
commonly defined carotid endarterectomy (CEA).
The first CEA was performed by Dr. Michael De-
Bakey in 1953 at the Methodist Hospital in Houston.
Since then, a large body of evidence on its effective-
ness in different patient groups has been accumu-
lated. Three studies have clearly shown the superior-
ity of CEA versus medical therapy in patients with a
symptomatic obstruction of a carotid artery: the Eu-
ropean Carotid Endarterectomy Surgery Trialist
(ECST) [25], the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) [7] and the
Veterans Affairs Cooperative Study (VACS) [26]. A
cumulative analysis of these studies, involving a to-
tal of 35.000 patients, considering a 5-year risk of ip-
silateral ischemic stroke reduction as primary end-
point, demonstrated that CEA was highly advanta-
geous in patients with a stenosis ≥70% (n=1095, ab-
solute risk reduction=16.0%, p <0.001), with a mild
benefit in those with 50-69% stenosis (n=1549, ab-
solute risk reduction 4.6%, p <0.04), no effect in pa-
tients with 30-49% stenosis (n=1429, absolute risk
reduction=3.2%, p <0.6), and even detrimental in
those with less than 30% stenosis (n=1746, absolute
risk increase= 2.2%, p <0.05) [27]. On the contrary,
the real benefit provided by CEA in asymptomatic
patients having a carotid obstruction is not clearly
understood. The two most important clinical trials on
this argument are the Asymptomatic Carotid Athero-
sclerosis Study (ACAS) [11] and the Asymptomatic
Carotid Surgery Trial (ACST) [28], randomizing pa-
tients with carotid artery stenosis in the absence of
symptoms to CEA or to medical therapy. ACAS has
shown an aggregate 5-year risk of ipsilateral stroke
and any perioperative stroke or death of 5.1% for
surgical patients and of 11.0% for patients treated
only with medical therapy [11]. ACST provided a 5-
year risk of stroke of 6.4% in the CEA-treated group
versus 11.8% in the control group, and, respectively,
a 5-year risk of 3.5% versus 6.1% for fatal or dis-
abling strokes and 2.1% versus 4.2% for fatal strokes
in the same groups [28]. Unlike ACAS, the benefit in
ACST was demonstrated for overall, fatal, disabling
and non-disabling strokes. Interestingly, the results
of these trials showed a significant difference among
men and women in terms of efficacy, with protective
effects greater for men. The benefit from CEA for
women was not demonstrated in the ACAS. In the
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ACST study, differently from man the absolute risk
reduction in women was not statistically significant,
and it seems that women who undergo CEA develop
many much more neurological complications [28]. 
According to the results of these large random-
ized clinical studies, both the AHA and, more re-
cently, the ESC guidelines recommend CEA in
symptomatic patients with a carotid stenosis greater
than 50% (but with the highest level of evidence
only for stenosis greater than 70%) as the first-line
choice for patients at low or intermediate surgical
risk [19, 20]. In patients with signs of progressive
minor stroke, revascularization must be performed
within three weeks [19, 20], while in cases of seri-
ous, disabling carotid strokes revascularization is
not indicated [19]. Regarding asymptomatic pa-
tients, guidelines indications are different: in this
setting AHA proposes CEA in case of stenosis
greater than 70% if the risk connected to the surgi-
cal procedure (stroke, myocardial infarction or death
for any causes) is acceptable [19]. For the same set-
up, ESC puts a lower cut-off, of more than 60%, if
the surgical risk is judged to be <3% and the patient
has a life expectancy greater than 5 years [20].
Guidelines do not recommend every attempt of
revascularization for stenosis <50% regardless from
symptoms (except in extraordinary circumstances),
for totally occluded vessels and for patients who
have experienced a large, severely disabling stroke,
which precludes preservation of useful cerebral
functions.
Endarterectomy is a serious surgical practice
and presents notable risks for the patients. The risks
associated with CEA involve neurological and non-
neurological complications. Neurological complica-
tions include periprocedural stroke, generally due to
a thromboembolic mechanism during or immedi-
ately after the procedure. In the North American
Symptomatic Endarterectomy Trial (NASCET), 43
of the 1087 patients undergoing CEA (4%) had a
non-disabling stroke, 17 (1.6%) had a non-fatal, dis-
abling stroke and 7 patients died for a stroke in the
30 days after endarterectomy [13]. As a conse-
quence of the ameliorated techniques, the CREST
trial reported an incidence of 2.3% of periprocedural
or ipsilateral stroke within 30 days of controlateral
operation (1.4% in previously asymptomatic pa-
tients and 3.2% in symptomatic patients) [6]. Minor
causes of strokes are due to cerebral low flow, for
both low systemic pressure and controlateral dis-
ease, poor collateral circulation, or reduced cere-
brovascular reserve. Hemorrhagic strokes are rare,
occurring in <1% of the procedures and accounting
for 5% of the perioperative strokes [29], as a result
of a suddenly increased perfusion in a patient with
prior severe stenosis and altered cerebral blood flow
autoregulation. This is known as cerebral hyperper-
fusion syndrome (CHS) and may be accompanied
by cerebral edema and seizures [30, 31]. On the
other hand, it must be noted that CHS and hemor-
rhagic strokes are even more common after stenting
procedures, probably as a consequence of the dual
antiplatelet therapy [32]. The risk of stroke after
CEA is greater in patients who had a symptomatic
obstruction of a carotid artery, hemispheric TIA
(versus retinal TIA), male gender, need for an urgent
revascularization due to ongoing cerebral damage,
reoperation versus primary surgery, ipsilateral is-
chemic lesion on computerized tomography, con-
tralateral carotid occlusion, poor collateral circula-
tion, impaired consciousness, and an irregular or ul-
cerated plaque [33, 34]. A further serious neurolog-
ical side event following CEA is cranial nerve paral-
ysis, happening in 7% of the patients undergoing
surgery and generally transient. In decreasing order
of frequency, hypoglossal, marginal mandibular, re-
current laryngeal, and spinal accessory nerves can
be involved or the Horner syndrome can be ob-
served. The risk of a permanent damage has been es-
timated of about 1%, and the only well recognized
risk factor for a nerve paralysis development seems
to be a duration of CEA > 2 hours [35-38]. Non-neu-
rological adverse events of surgery mainly derive
from general anesthesia and include cardiovascular
complications (principally myocardial infarction, in
about 2% of the treated subjects [39] hypertension
or hypotension [40], congestive heart failure, ar-
rhythmias and angina, rarely venous thromboem-
bolism [41]), pneumonia, wound infection, acute
thrombosis (prevented by the early administration of
aspirin) and arterial restenosis (with a frequency of
3.6% at 1 year, yet less than after stenting). Overall
mortality of CEA is reported to be of 1.3-1.8% [42].
So, there are some notable situations in which CEA
brings along severe risks or is not suitable. The first
is, obviously, the case of a patient at high surgical
risk. More strictly, according to the Stenting and An-
gioplasty Procedure in Patients at High Risk for En-
darterectomy (SAPPHIRE) trial, patients are consid-
ered to be at high-risk if they have, as co-morbidi-
ties, congestive heart failure (New York Heart Asso-
ciation class III/IV) and/or a known severe left ven-
tricular dysfunction, open heart surgery needed
within 6 weeks, a recent myocardial infarction or
unstable angina (and, if a coronary revascularization
is required, it should be performed after CEA), or a
severe pulmonary disease [43]. Also, a severe im-
pairment of hepatic or renal function has a signifi-
cantly negative impact on the outcome of CEA [44].
Another factor which relatively contraindicates
CEA is the presence of a lesion of the contralateral
laryngeal nerve, being the occurrence of a bilateral
paralysis threatening for the risk of laryngeal ob-
struction, airway limitation and the possible require-
ment of a tracheostomy [45, 46]. Finally, troubles
may concern the anatomy of the lesion. A high
carotid bifurcation or an atheromatous lesion that
extends into the internal carotid artery beyond the
exposed surgical field represents a technical chal-
lenge during CEA, and carotid lesions located at or
above the level of the second cervical vertebra are
particularly problematic. High cervical exposure in-
creases the risk of cranial nerve injury. These “high”
stenoses may represent a good field of application
for an endovascular revascularization. Similarly, le-
sions below the clavicle, prior radical neck surgery
or radiation, and controlateral carotid occlusion are
associated with higher risk. In these situations, the
ability and the experience of the surgeon may sig-
nificantly influence the outcome [47, 48]. 
In summary, CEA is an effective technique for
the prevention of stroke in patients having a carotid
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stenosis, particularly if they are symptomatic. How-
ever, as most surgical interventions, it may entail
important adverse effects, and in some situations it
should not be performed. In almost all of these con-
texts, carotid artery stenting (CAS) has proved to be
a safe and effective alternative.
The “state-of-art” of endovascular treatment 
Carotid artery stenting (CAS) has been initially
used as a second-choice, alternative treatment, ini-
tially in patients not eligible for surgery. Numerous
non-randomized and some randomized studies have
assessed safety and efficacy of carotid-artery stent-
ing in so-called high-risk patients [43, 49-52]. Al-
though CAS has been recommended in specialized
subsets of patients [6, 53-55] such as restenosis after
CEA, radiation-induced carotid stenosis, anatomi-
cally high lesions, increased cardiopulmonary risk
or with unfavorable neck anatomy and in higher-risk
patients, the appropriateness of its use in conven-
tional-risk patients remains an unsolved matter.
The potential benefits of endovascular treatment
(angioplasty with or without stent implantation) as
an alternative to carotid endarterectomy were first
highlighted by the Carotid and Vertebral Artery
Transluminal Angioplasty Study (CAVATAS) [56].
This trial showed that endovascular treatment largely
avoided the main complications of the endarterec-
tomy incision (namely cranial nerve injury and se-
vere hematoma). Besides, there was no statistical dif-
ference in terms of stroke or death at 30 days be-
tween CEA and angioplasty (the combined stroke
and death rate was 9.9% for CEA and 10% for en-
dovascular treatment, and death or disabling strokes
were observed in 5.9% of CEA patients and 6.4% of
endovascular patients, Table 1) [56]. It is worth men-
tioning that in the CAVATAS trial carotid stents were
used in only 26% of the patients who received an-
gioplasty, a factor that could have contributed to a
high incidence of recurrent ≥70% stenosis at 1 year
follow-up [57]. Despite these findings, there re-
mained no significant difference in ipsilateral stroke
between the groups with a hazard ratio of 1.04 [58].
Moreover, cerebral embolic protection devices were
unavailable at the time of the study, so this adjunct
was not used in the CAVATAS. Since completion of
CAVATAS, stenting has largely replaced the clinical
practice of angioplasty alone, and stents and protec-
tion devices specifically designed for the carotid
artery have been introduced. These early encourag-
ing results generated a great deal of interest in CAS,
and so, after CAVATAS, other large randomized tri-
als comparing CAS and CEA in symptomatic steno-
sis have been subsequently published exploring
short-term outcomes and longer term results. Among
these, the Stenting and Angioplasty with Protection
in Patients at High Risk for Endarterectomy (SAP-
PHIRE) trial [43] is the only randomized trial that
specifically enrolled high-risk patients to compare
CEA and CAS with embolic protection devices. The
primary endpoint (the composite of MI, stroke, or
death within 30 days plus death because of neuro-
logical causes or ipsilateral stroke between 31 days
and 1 year) occurred in 12.2% of patients assigned to
CAS and 20.1% of those assigned to CEA (Table 1).
In the periprocedural period (up to 30 days), the cu-
mulative incidence of stroke, myocardial infarction,
or death was 4.4 percent among patients who re-
ceived a stent and 9.9 percent among those who un-
derwent endarterectomy (p= 0.06). In the post-proce-
dural period, the cumulative incidence of the primary
end point at 30 days among these patients was 2.1%
among those who received a stent and 9.3% among
those who underwent endarterectomy. One-year
analysis in patients within the CAS arm also demon-
strated less cranial nerve paralysis (0% versus 4.9%;
p=0.004), reduced mean hospital stay (1.84 versus
2.85 days; p=0.002), and less target vessel revascu-
larization (0.5% versus 4.3%; p=0.04) [43]. The in-
vestigators of the SAPPHIRE trial concluded that
CAS was non-inferior to CEA, leading to US Food
and Drug Administration (FDA) approval of the
Cordis PRECISE nitinol stent for CAS.
The Stent-Protected Angioplasty versus Carotid
Endarterectomy (SPACE) trial randomized 1200
symptomatic patients. The incidence of ipsilateral
stroke or death at 30 days was the primary endpoint
of the study and did not differ between the groups
(6.3% for CEA vs. 6.8% for CAS, Table 1) [59]. Al-
though the two-year stroke plus 30-day stroke and
death rates were similar between the groups, the
SPACE trial failed to prove the non-inferiority of
CAS for the insufficient sample size. However, no
differences were found between CAS and CEA with
respect to the prevention of recurrent cerebrovascu-
lar events after treatment of severe symptomatic
carotid artery stenosis at 2 years. 
In the Endarterectomy versus Stenting in Pa-
tients with Symptomatic Severe Carotid Stenosis
(EVA-3S) trial the 30-day combined stroke and
death rate was higher in the CAS group (9.6%) com-
pared with 3.9% for CEA (Table 1) [60]. However,
these results have been criticized because of the po-
tential inexperience of CAS operators. Furthermore,
8.1% of CAS procedures were performed without an
embolic protection device, and in those with em-
bolic protection significantly fewer adverse events
were observed. Results up to 4 years show that there
was no difference in mortality between the two
treatment groups. The 4-year estimated cumulative
risks of periprocedural stroke or death and non-pro-
cedural ipsilateral stroke were significantly higher
after CAS than after CEA (Table 1). However, this
difference was largely accounted by the higher
periprocedural risk of CAS compared to CEA,
whereas the risk of ipsilateral stroke beyond the pe-
rioperative period was low and similar in both
groups [61].
The short-term results of the International
Carotid Stenting Study (ICSS), a randomized trial
comparing CAS versus CEA for recently sympto-
matic carotid artery stenosis, show that the risk of
stroke, death, or procedural myocardial infarction
120 days after randomization was significantly
higher in patients in the CAS group than in patients
in the CEA group (8.5% vs. 5.2%, Table 1) with an
hazard risk (HR) in favor of surgery of 1.69 (Table
1). The difference between groups was mainly due
to an excess of non-disabling stroke in the CAS
group compared to the CEA group, but there were
also more fatal strokes and fatal myocardial infarc-
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tions in the CAS group. By contrast, disabling
strokes in the two groups were identical and the rate
of disabling stroke or death was not significantly
different between groups. The balance of risk in fa-
vor of CEA caused by an excess of non-disabling
stroke in the CAS group might be seen as partly off-
set by the fact that CEA was associated with more
cranial nerve injuries and more severe hematomas
than CAS. Fewer procedural myocardial infarctions,
hematomas and cranial nerve paralyses were
recorded after CAS (RR 0.02, 95% CI 0.00-0.16,
p<0.0001). Taken together, the results of the CA-
VATAS, SAPPHIRE, SPACE and EVA-3S studies
strongly suggest that CAS is as effective as CEA for
the medium-term prevention of ipsilateral stroke, at
least for the first 4 years after the procedure. How-
ever, none of these studies was powered to show
equivalence between CAS and CEA with regard to
medium-term prevention of ipsilateral stroke. More
recently, the CREST trial enrolled 2522 participants
across North America, representing the largest ran-
domized clinical trial comparing the efficacy of
CAS to CEA and assessing the effects of carotid
revascularization in both symptomatic and asympto-
matic patients with carotid artery stenosis. In this
study there was no significant difference in the esti-
mated 4-year rates of stroke, myocardial infarction,
or death during the periprocedural period or ipsilat-
eral stroke between CAS and CEA (Table 1). Pa-
tients randomized to CAS had more periprocedural
strokes, but they had fewer myocardial infarctions
compared with those receiving CEA. The incidence
of major periprocedural strokes was low and not dif-
ferent between the two groups (0.9% vs. 0.6%; P =
0.52). Cranial nerve paralysis occurred in 0.3% of
patients randomized to CAS and in 4.7% of those
treated with CEA (HR 0.07, 95% CI 0.02-0.18; P =
0.0001). The rate of stroke or death among sympto-
matic patients after CAS (6.0%) was lower than the
corresponding rate observed in the SPACE trial
(6.8%, not including nonipsilateral stroke), the
EVA-3S trial (9.6%), and ICSS (7.4%). The rate of
stroke or death among symptomatic patients after
CEA (3.2%) was also lower than the corresponding
Table 1. - Randomized Trials Comparing Endarterectomy With Stenting in Symptomatic and Asymptomatic Patients
With Carotid Stenosis
Trial N. of Patients status Carotid artery stenosis (%) Primary endpoint HR
Patients (95% CI)
CAVATAS 504 Symptomatic or >50 Any disabling stroke or death 1.04 (0.64 to 1.64), p=0.90
asymptomatic CEA: 9.9%; CAS: 10.0%
SAPPHIRE 334 70% asymptomatic ≥80 in asymptomatic patients; The composite of MI, stroke, =0.004 for non inferiority 
30% symptomatic ≥50% in symptomatic patients or death (16.4 to 0.7)
CEA: 12.2%; CAS: 20.1%
SAPPHIRE 260 Symptomatic ≥80 in asymptomatic patients; Stroke: CEA: 9.0%;CAS: 9.0% Stroke: p=0.99 (-6.1 to 6.1)
Follow up or asymptomatic ≥50% symptomatic patients Death: CEA: 21%; CAS: 18.6% Death:p=0.68 (10.9 to 6.1)
at 3 years
SPACE 1183 Symptomatic ≥70 Ipsilateral stroke or death RR 1.07 (0.70-1.63)
CEA: 6.3%; CAS: 6.8%
SPACE 1214 Symptomatic ≥70 Any periprocedural stroke 
Follow up or death RR 1.10 (0.75-1.61)
p=0.62
at 2 years CEA: 8.8%; CAS: 9.5%
EVA-3S 527 Symptomatic ≥60 Any stroke or death RR 2.5 (1.2-5.1), p=0.01
CEA: 3.9%; CAS: 9.6%
EVA-3S 527 Symptomatic ≥60 Cumulative risks of periprocedural 1.97 (1.06-3.67), p=0.03
Follow up stroke or death and non-procedural 
at 4 years ipsilateral stroke
CEA: 6.2%; CAS: 11.1%
ICSS 1713 Symptomatic >50 Any stroke, death, or procedural 1.69 (1.16-2.45), p=0,006
MI at 120 days
CEA: 8.5%; CAS: 5.2%
CREST 2502 Symptomatic ≥70 on ultrasound Any stroke, MI, or death during the 1.11 (0.81-1.51) p=0.51
or asymptomatic ≥50 on angiography in periprocedural period or ipsilateral 
symptomatic patients stroke within 4 years after 
≥60 on angiography in randomization
asymptomatic patients CEA: 6.8%; CAS: 7.2%
CAS: Carotid Angioplasty and Stenting; CAVATAS: Carotid and Vertebral Artery Transluminal Angioplasty Study; CEA: Carotid Endarterectomy;
CREST: Carotid Revascularization Endarterectomy vs Stenting Trial; EVA-3S: Endarterectomy vs Angioplasty in Patients with Symptomatic Severe
Carotid Stenosis; ICSS: International Carotid Stenting Study; MI: myocardial infarction; SAPPHIRE: Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy; SPACE: Stent-protected Percutaneous Angioplasty of the Carotid vs Endarterectomy
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percentage in SPACE (6.3%) and was similar to the
corresponding percentage in EVA-3S (3.9%) as well
as that in ICSS (3.4%).
The improved periprocedural outcomes in
CREST as compared to previous trials may reflect
the effective surgeon credentialing, assimilation of
evolving endovascular technology, and rigorous
training and credentialing of CAS operators [62].
These aspects are of crucial interest in determining
the efficacy and safety of CAS: indeed, ESC guide-
lines describe the differences in CAS outcomes be-
tween centers and interventionists with low or high
experience and number of cases, underlining thus the
need for a great operator experience [20]. Moreover,
it is worth considering that CAS technique and ma-
terials have been evolving rapidly in the last few
years, also respect to CREST trial, and that outcomes
analysis has been doubtless influenced by these im-
provements, suggesting that, in the next future, a fur-
ther outcomes improvement could be obtained. 
Recent large trials like CREST make it clear that
with adequate training, physicians can perform CAS
and CEA with low complication rates. Taken to-
gether with the results of previous trials, it appears
that CAS is associated with a higher periprocedural
risk of stroke or death. However, it should be con-
sidered that the aim of treatment for carotid stenosis
is long-term prevention of stroke. The EVA-3S and
SPACE trials showed little difference between CAS
and CEA groups in the rates of ipsilateral non-peri-
operative stroke occurring more than 30 days after
treatment, but the length of follow-up in these trials
was restricted to a maximum of 4 years and 2 years,
respectively. In particular, in the SPACE, at 2 years,
the ipsilateral stroke rate was approximately 1% per
year for CEA and CAS when periprocedural events
were excluded. The clinical durability of CEA and
CAS beyond 5 years cannot be clearly determined
from available studies [55, 61]. CAVATAS had a
longer follow-up period and reported a higher 8-year
rate of non-perioperative stroke in patients who re-
ceived endovascular treatment (21.1%) than in pa-
tients who received surgery (15.4%; HR 1.66, 95%
CI 0.99-2.80). Most of the divergence occurred
more than 2 years after randomization, which might
be partly explained by a higher incidence of resteno-
sis after endovascular treatment than after en-
darterectomy. However, CAVATAS included only a
small proportion of patients treated by stent implan-
tation, and the long-term rate of restenosis after this
strategy remains uncertain. Follow-up is therefore
continuing in ICSS and further data will become
available from the current trials. In the CREST
study, the rates of ipsilateral stroke during the fol-
low-up period (2.0% with CAS and 2.4% with CEA)
were similar to those in SPACE and EVA-3S, sug-
gesting an excellent durability for up to 4 years.
Hence, additional long-term data are needed before
clear conclusions can be drawn regarding the rela-
tive risks and benefits of the 2 procedures [63]. Clin-
icians should also carefully consider the relation be-
tween patient age and outcomes of CAS and CEA.
In most of these studies, an effect of age on differ-
ences between CAS and CEA was found, with
younger patients having a slightly better outcome
with CAS and older patients having a better out-
come with CEA. The CAVATAS trial examined pa-
tients younger than 68 years and found no signifi-
cant difference in the rate of stroke or perioperative
death between the endovascular and surgery group.
However, patients older than 68 years demonstrated
a non-significant trend toward more adverse out-
comes with endovascular therapy [64]. The EVA3-S
trial reported excess risk associated with CAS in ≥
70 years patients [61, 65]. Similarly, the SPACE trial
demonstrated an odds ratio in favor of surgery in pa-
tients older than 75 years [66]. The CREST lead-in
results demonstrated worse outcomes in patients 75
years of age and older. The 30-day rate of stroke and
death in the CAS arm compared to the CEA arm was
significantly higher in older subjects in both symp-
tomatic (9.1% vs. 4.5%), as well as asymptomatic
populations (7.5% vs. 2.4%). The odds ratio for ad-
vanced age and the primary endpoint of 30-day
stroke, MI, and death was 2.38. Preliminary data
from CREST demonstrated improved outcomes in
patients younger than 69 years of age undergoing to
CAS, while patients older than 70 years of age fared
better with CEA [67]. Mechanisms underlying the
increased risk with CAS in octogenarians probably
include increased aortic arch complexity and calcifi-
cation, greater vessel tortuosity and calcification
[68, 69] and less cerebral reserve compared with a
younger population. So that, even though the elderly
patient certainly presents with increased risk to both
surgical and endovascular interventions, at present,
the data favor CEA in the octogenarian population.
Finally, controlateral carotid occlusion is a well-
documented predictor for 30-day stroke or death in
patients undergoing CEA [70]. Naggara et al. con-
firm that controlateral occlusion is not associated
with an increase in risk of adverse events in CAS
[71, 72], which is consistent with the fact that CAS
requires shorter carotid occlusion than CEA. This
result may help to identify a potential target popula-
tion for CAS. 
Conclusions
Recent results of large randomized clinical trials
indicate that outcomes are improving for patients re-
quiring treatment for carotid artery stenosis, either
for interventional or medical treatment. While med-
ical therapy alone is considered the gold standard for
patients with asymptomatic stenosis of carotid
artery, intervention confers an outcome benefit in
symptomatic patients. In the last few years CAS has
emerged as a valid alternative to CEA, which is still
indicated as the best therapy. The results of random-
ized trials have not shown consistent outcome dif-
ferences between CAS and CEA. CAS is associated
with major periprocedural risks of stroke and death,
while CEA is associated with increased incidence of
myocardial infarction and cranial nerve paralysis.
CAS may be superior to CEA in certain groups of
patients, such as those exposed to previous neck
surgery or radiation injury. When performed in con-
junction with an embolic protection device, the risks
associated with CAS may be lower than those asso-
ciated with CEA in patients at elevated risk of sur-
gical complications. The selection of patients for ei-
ther CEA or CAS may require attention to age, with
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patients younger than 60 years having a slightly bet-
ter outcome with CAS, patients older than 70 years
having a better outcome with CEA and those
younger than 70 years having an equivalent or bet-
ter aggregate outcome with CAS. Follow-up of on-
going clinical trials will provide new data regarding
relative costs and benefits of CAS versus CEA,
long-term restenosis rates and a better definition of
subgroups that may benefit from specific interven-
tions. However, the rapid evolution in CAS tech-
nique and materials suggests a great potential for
CAS to improve outcomes and demonstrate superi-
ority compared to CEA in the next future.
Riassunto
La stenosi aterosclerotica dei vasi carotidei è un
noto fattore di rischio per lo sviluppo di ictus ische-
mico e la rivascolarizzazione si è dimostrata lo stru-
mento migliore per la prevenzione, in particolare
nei pazienti che presentano una sintomatologia de-
rivante dalla stenosi. Per oltre 50 anni la strategia
di rivascolarizzazione di prima scelta è stata l’en-
doarterectomia carotidea (CEA), ma negli ultimi
anni il trattamento endovascolare mediante angio-
plastica ed impianto di stent (CAS) si è dimostrato
una valida alternativa. Recentemente, sono emersi
numerosi interessanti studi di confronto tra le due
strategie terapeutiche. Il CAS sembra associato a
maggior numero di ictus periprocedurali, ma con
minori eventi avversi legati alla chirurgia e all’ane-
stesia generale, e pertanto è stato inizialmente con-
siderato la seconda scelta riservata a pazienti nei
quali la chirurgia era controindicata. Tuttavia, studi
clinici più recenti hanno rivelato che il CAS possa
essere considerato un’efficace alternativa alla CEA.
Inoltre, la rapida evoluzione delle tecniche e dei ma-
teriali utilizzati nel CAS suggerisce la possibilità
che nel prossimo futuro esso possa dimostrare supe-
riorità rispetto alla CEA. Scopo di tale revisione è
approfondire lo stato dell’arte delle evidenze clini-
che riguardanti il trattamento delle stenosi caroti-
dee, con particolare attenzione alla terapia endova-
scolare.
Parole chiave: carotide, stenosi, CREST, CAS,
CEA.
ABBREVIATIONS LIST 
ACAS: Asymptomatic Carotid Atherosclerosis Study
ACST: Asymptomatic Carotid Surgery Trial
AHA: American Heart Association 
CAPRIE: Clopidogrel versus Aspirin in Patients at Risk of Is-
chaemic Events
CAVATAS: Carotid and Vertebral Artery Transluminal Angio-
plasty Study
CAS: Carotid Artery Stenting
CEA: Carotid Endarterectomy 
CHS: Cerebral Hyperperfusion Syndrome 
CREST: Stenting versus Endarterectomy for Treatment of
Carotid-Artery Stenosis 
ECST: European Carotid Endarterectomy Surgery Trialist
EPD: Embolic Protection Device
ESC: European Society of Cardiology 
EVA-3S: Endarterectomy versus Stenting in Patients with
Symptomatic Severe Carotid Stenosis
HR: Hazard Risk; 
ICSS: International Carotid Stenting Study
MI: Myocardial Infarction
NASCET: North American Symptomatic Carotid Endarterec-
tomy Trial 
RCT: Randomized Controlledlinical Trial
SAPPHIRE: Stenting and Angioplasty with Protection in Pa-
tients at High Risk for Endarterectomy
SPACE: Stent-Protected Angioplasty versus Carotid En-
darterectomy
TIA: Transient Ischemic Attack 
VACS: Veterans Affairs Cooperative Study
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